Cue Biopharma, Inc.
NASDAQ:CUE · NASDAQ Capital Market
-$2.56 today
Vol 0.06M · Avg 0.76M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-100.6%
avg -88.4%
ROIC
-86.6%
avg -71.5%
ROA
-63.0%
avg -61.2%
Analysis
ROA is currently the strongest return metric at -63.0% versus its period average of -61.2%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Lucinda Warren | Principal Fin & Accounting Off. and Chief Financial & Business Officer | $470,948.00 | — | 57 | $250,000.00 | 9.51% |
Colin G. Sandercock | Senior Vice President of Intellectual Property | $449,642.00 | — | 69 | $100,000.00 | 3.81% |
Shao-Lee Lin | President, CEO & Director | $434,202.00 | — | 59 | $90,906.00 | 3.46% |
Ronald D. Seidel | Co-Founder | $316,628.00 | — | 50 | $75,000.00 | 2.85% |
Rodolfo J. Chaparro | Co-Founder | $316,628.00 | — | 53 | $10,000.00 | 0.38% |
Sumita Ray | Chief Legal & Compliance Officer and Corporate Secretary | — | — | 52 | $0.00 | <0.01% |
Steven C. Almo | Co-Founder and Chairman of Scientific & Clinical Advisory Board | — | — | 65 | $8,000.00 | 0.30% |
Daniel G. Baker | Interim Chief Development Officer | — | — | 76 | $1,626.00 | 0.06% |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
7
$599,821.17
Sells
0
$0.00
Net Sentiment
+$599,821.17
Net buying
Most Active
Sarraf Pasha
5 transactions
Analysis
Insiders reported 7 buys worth $599,821.17 and 0 sells worth $0.00 over the last 12 months. That adds up to net buying of $599,821.17. Sarraf Pasha was the most active insider with 5 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | N/A | -11.7% (10yr)1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Forward estimates point to Revenue at -11.7% (10yr), giving you a quick read on expected growth from here.
Competitors
Peer companies in the same sector
Century Therapeutics, Inc.
NASDAQ:IPSC
$194.78M
Equillium, Inc.
NASDAQ:EQ
$99.82M
Spruce Biosciences, Inc.
NASDAQ:SPRB
$71.19M
NRx Pharmaceuticals, Inc.
NASDAQ:NRXP
$66.38M
Coeptis Therapeutics, Inc.
COEP
$57.63M
Outlook Therapeutics, Inc.
NASDAQ:OTLK
$50.19M
Barinthus Biotherapeutics plc
BRNS
$27.41M
Senti Biosciences, Inc.
SNTI
$25.24M
Medicus Pharma Ltd. Common Stock
MDCX
$7.44M
IO Biotech, Inc.
IOBT
$885,690.00
Who manages CUE?
Cue Biopharma, Inc. (CUE) lists 8 active executives. The top listed executive is Ronald D. Seidel, Co-Founder.
Are CUE insiders buying or selling?
Recent insider activity shows net buying of $48.48M.
Explore More
Continue the stock analysis
Jump to another research area for this company.